(Q47817656)

5 February 2018

title

Ex vivo malignant glioma cells are sensitive to Fas (CD95/APO-1) ligand-mediated apoptosis (English)

1 reference

5 February 2018

author name string

Frei K

1

1 reference

5 February 2018

Ambar B

2

1 reference

5 February 2018

Adachi N

3

1 reference

5 February 2018

Yonekawa Y

4

1 reference

5 February 2018

Fontana A

5

1 reference

5 February 2018

publication date

1 July 1998

1 reference

5 February 2018

Journal of Neuroimmunology

published in

1 reference

5 February 2018

volume

87

1 reference

5 February 2018

issue

1-2

1 reference

5 February 2018

page(s)

105-113

1 reference

5 February 2018

The p53 gene and its role in human brain tumors.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900065-4

7 January 2021

Randomised, controlled study of intratumoral recombinant gamma-interferon treatment in newly diagnosed glioblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900065-4

7 January 2021

Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900065-4

7 January 2021

Apoptosis in cancer therapy: crossing the threshold

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900065-4

7 January 2021

Involvement of the CD95 (APO–1/Fas) receptor/ligand system in drug–induced apoptosis in leukemia cells

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900065-4

7 January 2021

Fas ligand expression in glioblastoma cell lines and primary astrocytic brain tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900065-4

7 January 2021

Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900065-4

7 January 2021

Characterization and chemosensitivity of two cell lines derived from human glioblastomas

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900065-4

7 January 2021

Metalloproteinase-mediated release of human Fas ligand

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900065-4

7 January 2021

Apoptosis. Its significance in cancer and cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900065-4

7 January 2021

The proto-oncogene Bcl-2 and its role in regulating apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900065-4

7 January 2021

Estimation of cell number by neutral red content. Applications for proliferative and survival assays

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900065-4

7 January 2021

Comparative study of p53 gene and protein alterations in human astrocytic tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900065-4

7 January 2021

p53-dependent apoptosis modulates the cytotoxicity of anticancer agents

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900065-4

7 January 2021

National survey of patterns of care for brain-tumor patients

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900065-4

7 January 2021

Regulation of cell surface APO-1/Fas (CD95) ligand expression by metalloproteases

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900065-4

7 January 2021

Apoptosis and cancer: the failure of controls on cell death and cell survival.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900065-4

7 January 2021

Fas antigen mRNA induction in postischemic murine brain

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900065-4

7 January 2021

Apoptosis by death factor

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900065-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900065-4

1 reference

7 January 2021

The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900065-4

7 January 2021

Lethal effect of the anti-Fas antibody in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900065-4

7 January 2021

Bcl-2 and the regulation of programmed cell death

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900065-4

7 January 2021

Local Fas/APO-1 (CD95) ligand-mediated tumor cell killing in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900065-4

7 January 2021

Neurons induced to express major histocompatibility complex class I antigen are killed via the perforin and not the Fas (APO-1/CD95) pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900065-4

7 January 2021

Immunochemotherapy of malignant glioma: synergistic activity of CD95 ligand and chemotherapeutics.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900065-4

7 January 2021

Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain?

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900065-4

7 January 2021

Gene therapy for glioblastoma [correction of gliobestome] multiform: in vivo tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900065-4

7 January 2021

Preferential expression of Fas/APO1 (CD95) and apoptotic cell death in perinecrotic cells of glioblastoma multiforme.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900065-4

7 January 2021

Expression of the functional soluble form of human fas ligand in activated lymphocytes.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900065-4

7 January 2021

Apoptosis in the pathogenesis and treatment of disease

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900065-4

7 January 2021

Monoclonal antibody-mediated tumor regression by induction of apoptosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900065-4

7 January 2021

The effects of local and systemic interferon beta (Fiblaferon) on supratentorial malignant cerebral glioma--a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900065-4

7 January 2021

Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900065-4

7 January 2021

Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900065-4

7 January 2021

Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900065-4

7 January 2021

Clinical effect of intra-arterial tumor necrosis factor-alpha for malignant glioma.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900065-4

7 January 2021

In vitro chemosensitivity testing and its clinical application in human gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900065-4

7 January 2021

Intravenous recombinant interferon beta in patients with recurrent malignant gliomas: a phase I/II study

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900065-4

7 January 2021

10.1016/S0165-5728(98)00065-4

Identifiers

DOI

1 reference

5 February 2018

PubMed ID

9670851

1 reference

5 February 2018